Please ensure Javascript is enabled for purposes of website accessibility

What's Behind Eli Lilly's Mixed Q1 Results

By Keith Speights – Apr 30, 2019 at 3:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The big drugmaker missed Wall Street revenue expectations in Q1 but narrowly beat earnings estimates. Here's what you need to know.

Eli Lilly and Company (LLY 0.35%) reported improvements when it announced its fourth-quarter results in February. Revenue increased by 5% year over year while adjusted earnings per share (EPS) were up by 17%.

Investors learned how Eli Lilly performed in the first quarter on Tuesday when the company provided a quarterly update before the market opened. How did Eli Lilly fare? Here's what you need to know about the company's first-quarter results.

physician drawing up a medication from a vial

Image source: Getty Images.

By the numbers

Eli Lilly reported revenue in the first quarter of $5.1 billion. This reflected a 3% increase from the prior-year period revenue total of $4.96 billion. The consensus Wall Street analysts' estimate had projected Q1 revenue of $5.22 billion.

On a generally accepted accounting principles (GAAP) basis, Eli Lilly's net income in the first quarter was $4.24 billion, or $4.31 per share. The company's bottom line reflected a 250% increase from the prior-year period GAAP net income of $1.2 billion, or $1.16 per share.

The company's adjusted non-GAAP net income in the first quarter was $1.24 billion, or $1.33 per share. In the prior-year period, Lilly announced adjusted net income of $1.29 billion, or $1.31 per share. The company's Q1 adjusted EPS was slightly better than the consensus analysts' estimate of $1.32 per share.

Behind the numbers

Probably the best news for Lilly in the first quarter was an exceptionally strong performance for several of its top drugs. Psoriasis and psoriatic arthritis drug Taltz was a huge winner, with sales skyrocketing by 72% to more than $252 million.

There were also several bright spots in Lilly's diabetes franchise. Sales for Trulicity jumped 30% year over year to nearly $880 million. Insulin product Basaglar's sales soared 51% to $251 million. Sales for Jardiance rose 35% to nearly $204 million.

On the other hand, not everything was positive for Lilly. Sales for Cialis fell 38% year over year to $308 million due to generic competition. The company's insulin products Humalog and Humulin also experienced sales declines. Sales for Humalog dropped 8% to just under $731 million, while sales for Humulin slipped 9% to $298 million.

Key developments in Eli Lilly's first quarter include the completed disposition of the company's ownership of the Elanco Animal Health business and completion of the acquisition of Loxo Oncology.

Looking ahead

The company adjusted its full-year 2019 guidance as a result of the disposition of its Elanco business. Eli Lilly now expects full-year revenue between $22 billion and $22.5 billion, down from its previous outlook of 2019 revenue between $25.1 billion and $25.6 billion.

However, Lilly boosted its earnings guidance for 2019. The drugmaker projects GAAP EPS of between $8.57 and $8.67, up from its previous forecast of a range of $4.57 to $4.67. Non-GAAP EPS is expected to be between $5.60 and $5.70, up from previous guidance of $5.55 to $5.65.

In addition, CEO David Ricks specifically mentioned the potential 2020 launch of Loxo Oncology's late-stage cancer candidate LOXO-292 as something to look forward to. Investors will also want to watch how Lilly's new migraine drug Emgality performs. 

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Eli Lilly and Company Stock Quote
Eli Lilly and Company
$366.53 (0.35%) $1.28

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.